On the GARDP website, find the 'GARDP Strategy 2024-2028' page. Identify the three main criteria that form GARDP's disease area strategy and briefly describe each. Also, state the key characteristic of GARDP’s unique antibiotic R&D partnership model.
Navigate to gardp.org. From the main navigation, click on 'Our programmes'. Click on 'Serious bacterial infections & sepsis'. Scroll down and click the 'LEARN MORE' link associated with 'Goal 3: Expand portfolio to develop new treatment(s) for target pathogens, in line with 2024-2028 GARDP Strategy'. On the 'GARDP Strategy 2024-2028' page, scroll down to locate the section describing GARDP’s unique antibiotic R&D partnership model and its key characteristic. Continue scrolling down the 'GARDP Strategy 2024-2028' page to find the three criteria for GARDP's disease area strategy. Extract the three criteria and their brief descriptions.
Successfully navigate to the 'GARDP Strategy 2024-2028' page. Accurately list the three main criteria (priorities) for GARDP's disease area strategy: - Prioritizes serious bacterial infections and sepsis (including neonatal sepsis) and sexually transmitted infections (with a focus on gonorrhoea). - Targets WHO priority pathogens that are responsible for particularly deadly and debilitating drug-resistant infections. - Concentrates its efforts on populations who are disproportionately affected by drug resistance—like newborns, children and women, particularly in low- and middle-income countries. For each criterion, provide a brief and accurate description of its core objective. Identify and state the key characteristic of GARDP's 'unique antibiotic R&D partnership model' as: 'enabling the right antibiotic treatments to be developed and made available to people who need them'.